A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer
Complete title: A Phase 1, Open-Label, Dose-Escalation Study ofOlaratumab as a Single Agent and in Combination withDoxorubicin, Vincristine/Irinotecan, or High-DoseIfosfamide in Pediatric Patients with Relapsed orRefractory Solid Tumors
|Doug Hawkins, MD
The main purpose of this study is to evaluate the safety of different doses of olaratumab and to determine which dose should be used for future pediatric studies. The present study is open to children with advanced cancer or cancer that has spread to another part of the body. The study has two parts. In each part, a specific dose of olaratumab will be given for 21 days, followed by one of three standard chemotherapy regimens. Participants will only enroll in one part.
** For Eligibility information, please click on the "Look up trial at NIH" link above. **
Other eligibility criteria may apply.
Solid Tumors; Neoplasms; Neoplasm Metastasis
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
- Talk to your health care providers first before making decisions about your health care.
- Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.